	US 11,952,631 B2
	Diagnostics and therapy for human respiratory syncytial virus
Daniel Todt, Hannover (DE); Sibylle Haid, Hannover (DE); Martin Wetzke, Hannover (DE); Gesine Hansen, Hannover (DE); Chris Lauber, Dresden (DE); Lars Kaderali, Greifswald (DE); and Thomas Pietschmann, Hannover (DE)
Assigned to MEDIZINISCHE HOCHSCHULE HANNOVER, Hannover (DE); TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, Hannover (DE); and TECHNISCHE UNIVERSITÄT DRESDEN, Dresden (DE)
Appl. No. 16/754,390
Filed by MEDIZINISCHE HOCHSCHULE HANNOVER, Hannover (DE); TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, Hannover (DE); and TECHNISCHE UNIVERSITÄT DRESDEN, Dresden (DE)
PCT Filed Oct. 9, 2018, PCT No. PCT/EP2018/077385 § 371(c)(1), (2) Date Apr. 8, 2020, PCT Pub. No. WO2019/072789, PCT Pub. Date Apr. 18, 2019.
Claims priority of application No. 17195522 (EP), filed on Oct. 9, 2017.
Prior Publication US 2020/0283848 A1, Sep. 10, 2020
Int. Cl. C12N 15/11 (2006.01); A61K 31/7105 (2006.01); A61K 48/00 (2006.01); C12N 15/113 (2010.01); C12Q 1/6883 (2018.01)

CPC C12Q 1/6883 (2013.01) [A61K 31/7105 (2013.01); A61K 48/005 (2013.01); C12N 15/1131 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01)]

3 Claims

1. A method for treatment of a HRSV infection in a subject in need of the treatment, comprising administering to the subject an agonist of transmembrane protein 259 (TMEM259);

wherein the agonist is an expression construct comprising at least one promoter operably linked to a downstream gene of TMEM259 or a downstream TMEM259 coding region.